This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 May 2011

SARcode Announces Positive Clinical Results of Dry Eye Treatment

SARcode Corporation presented study results for their lead investigational molecule, SAR 1118.

SARcode Corporation announced this week that its SAR 1118 molecule has shown encouraging results in a Phase II Study of dry eye disease. SAR 1118 is an integrin antagonist that inhibits T-cell mediated inflammation, a key component of dry eye disease.


The results of the trial, which involved 230 patients with dry eye disease, indicated that the subjects receiving SAR 1118 experienced a reduction in corneal staining, increased tear production and improved visual-related function compared to the placebo.


SARcode Corporation chief medical officer Charles Semba said that the company is encouraged by the clinical effects of SAR 1118 in improving both the signs and symptoms of dry eye, which supports th

Related News